These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 6340415)
1. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Schiøtz PO; Jørgensen M; Flensborg EW; Faerø O; Husby S; Høiby N; Jacobsen SV; Nielsen H; Svehag SE Acta Paediatr Scand; 1983 Mar; 72(2):283-7. PubMed ID: 6340415 [TBL] [Abstract][Full Text] [Related]
2. Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection. Schiøtz PO; Nielsen H; Høiby N; Glikmann G; Svehag SE Acta Pathol Microbiol Scand C; 1978 Feb; 86(1):37-40. PubMed ID: 707104 [TBL] [Abstract][Full Text] [Related]
3. Activated complement in the sputum from patients with cystic fibrosis. Schiøtz PO; Sørensen H; Høiby M Acta Pathol Microbiol Scand C; 1979 Feb; 87C(1):1-5. PubMed ID: 433601 [TBL] [Abstract][Full Text] [Related]
4. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. Kronborg G APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034 [TBL] [Abstract][Full Text] [Related]
5. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM; Waugh J; Noble S Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360 [TBL] [Abstract][Full Text] [Related]
6. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle. Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750 [TBL] [Abstract][Full Text] [Related]
9. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872 [TBL] [Abstract][Full Text] [Related]
10. Autoantibodies in serum and sputum from patients with cystic fibrosis. Schiøtz PO; Egeskjold EM; Høiby N; Permin H Acta Pathol Microbiol Scand C; 1979 Oct; 87(5):319-24. PubMed ID: 117671 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871 [TBL] [Abstract][Full Text] [Related]
12. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. Kronborg G; Shand GH; Fomsgaard A; Høiby N APMIS; 1992 Feb; 100(2):175-80. PubMed ID: 1554493 [TBL] [Abstract][Full Text] [Related]
14. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277 [TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry. Petersen TD; Ciofu O; Pressler T; Giwercman B; Pedersen SS; Høiby N Thorax; 1996 Jul; 51(7):733-8. PubMed ID: 8882082 [TBL] [Abstract][Full Text] [Related]
16. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum. Schiller NL; Millard RL Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945 [TBL] [Abstract][Full Text] [Related]
17. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Döring G; Dorner F Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758 [TBL] [Abstract][Full Text] [Related]
18. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Valerius NH; Koch C; Høiby N Lancet; 1991 Sep; 338(8769):725-6. PubMed ID: 1679870 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284 [TBL] [Abstract][Full Text] [Related]
20. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. Hyatt AC; Chipps BE; Kumor KM; Mellits ED; Lietman PS; Rosenstein BJ J Pediatr; 1981 Aug; 99(2):307-14. PubMed ID: 7019407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]